A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors Abstract #783

Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Aim(s): To compare the sensitivities of three different CgA assays in NET patients.
Materials and methods: We measured CgA in 42 NET patients (male/female: 23/19, median age: 63 years (range 29-85 years)). Twenty-five patients had liver metastases, eight had local disease, and nine were disease-free after surgery. We studied a RIA in-house assay (RH RIA assay) (Rigshospitalet, Copenhagen, Denmark); NEOLISATM (Euro Diagnostica, Malmö, Sweden) and EURIA CgA RIA (Euro Diagnostica, Malmö, Sweden).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result